Skip to content

Based on VBM to investigate the effect of acupuncture-rehabilitation therapy on hippocampal volume and its neuroprotective mechanism in patients with vascular cognitive impairment with T2DM

Based on VBM to investigate the effect of acupuncture-rehabilitation therapy on hippocampal volume and its neuroprotective mechanism in patients with vascular cognitive impairment with T2DM

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100047803
Enrollment
Unknown
Registered
2021-06-26
Start date
2021-07-01
Completion date
Unknown
Last updated
2022-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vascular cognitive dysfunction

Interventions

Sponsors

The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. VCI inclusion criteria for patients with T2DM : (1) Conforming to the diagnostic points of T2DM and VCI, and having a history of ischemic or hemorrhagic stroke confirmed by cranial CT or MRI; (2) Cognitive impairment with a Montreal Cognitive Assessment Scale (MOCA - Beijing Version) score =24 points.The clinical dementia scale (CDR) score was 0.5. The clinical dementia scale (CDR) score was 0.5.No significant impairment in daily living activities, instrumental daily living ability scale (IADL) score >=16; (3) can cooperate with the completion of nuclear magnetic functional scanning; (4) The course of stroke ranged from 3 to 12 months; (5) People aged 50 to 60 are right-handed; (6) No speech and language dysfunction; (7) Have not received acupuncture or rehabilitation treatment in the past three months; (8) No diseases or infectious diseases such as depression and mental symptoms; (9) No use of drugs in the following categories within 30 days prior to screening for cognitive impairment: drugs for Alzheimer's disease or dementia, anti-Parkinson's disease drugs, short-acting antianxiety agents, neurosedatives or analgesics, antiepileptics, hormones, drugs with significant cholinergic or anticholinergic side effects. 2. Inclusion criteria for T2DM group with normal cognitive function : (1) meeting the diagnostic criteria for diabetes, and excluding stroke confirmed by cranial CT or MRI; (2) Normal cognitive function, MOCA scale score >=26 points (if the number of years of education =24 points;CDR score was 0;Instrumental Daily Living Scale (IADL) score >=16 points; (3) can cooperate with the completion of nuclear magnetic functional scanning; (4) People aged 50 to 60 are right-handed; (5) No speech and language dysfunction; (6) Have not received acupuncture or rehabilitation treatment in the past three months; (7) No diseases or infectious diseases such as depression and mental symptoms; (8) No use of drugs in the following categories within 30 days before screening for cognitive impairment: drugs for Alzheimer's disease or dementia, anti-Parkinson's disease drugs, short-acting antianxiety agents, neurosedatives or analgesics, antiepileptics, hormones, drugs with significant cholinergic or anticholinergic side effects. 3. Inclusion criteria for healthy volunteers : (1) They did not meet the diagnostic criteria for diabetes and were confirmed by cranial CT or MRI to exclude stroke; (2) Normal cognitive function, MOCA scale score >=26 points (if the number of years of education =24 points;CDR score was 0;Instrumental Daily Living Scale (IADL) score >=16 points; (3) can cooperate with the completion of nuclear magnetic functional scanning; (4) 50 to 60 years old, right-handed; (5) no brain trauma, drug and alcohol dependence may affect the brain structure and function of diseases;No depression, mental symptoms and other diseases.

Exclusion criteria

Exclusion criteria: 1. Subjects with obvious hearing, visual and language impairments affecting cognitive function tests; 2. Acute diabetic complications such as diabetic ketoacidosis and high-level coma in the past 3 months; serious diseases such as heart, lung, liver, kidney and blood system may affect cognitive function; 3. People with central infection, brain tumor or other focal injury affecting cognition; suffering from Alzheimer's disease, Parkinson's disease and other neurological diseases that can cause dementia; history of severe brain trauma with persistent neurological deficits or known structural brain abnormalities; 4. History of alcohol, drug abuse or dependence within the past 2 years.

Design outcomes

Primary

MeasureTime frame
voxel-based morphometry;Superoxide Orgotein Dismutase;Maleic Dialdehyde;brain derived neurotrophic factor;

Secondary

MeasureTime frame
Montreal CognitiveAssessment;Revised Wechsler Memory Inventory, Version 4 (Chinese Version);Function Independent Measure;

Countries

China

Contacts

Public ContactGuan Ying

The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine

18800462510@163.com+86 18800462510

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 13, 2026